You and I usually agree. But I will have to disagree with you on this one. My analysis is as follows: Brilacidin worked very well against ABSSSI bacteria in the lab. Then it worked very well against the ABSSSI bacteria in the human body. Now we know that it worked very well against the Covid-19 virus in the lab. Since it worked against the ABSSSI bacteria in the lab and in the human body, and it worked against the virus in human tissue in the lab; I am very optimistic that Brilacidin will work against the virus in the human body. It’s possible that there is some unknown differential factor that could make it more difficult for Brilacidin to kill the virus as opposed to bacteria in the human body. But I think that is extremely unlikely. So in this upcoming Phase 2 clinical trial, I think that the chances of Brilacidin’s success are more like 90% rather than 50% as you indicate.

Here Today said, “Every clinical trial or testing has a 50 / 50 chance of succeeding or failing.”